Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis

Anthony Mills, Mark Nelson, Dushyantha Jayaweera, +8

AIDS

Evolution of Treatment-Emergent Resistant Variants in Telaprevir Phase 3 Clinical Trials

James C. Sullivan, Sandra De Meyer, Doug J. Bartels, +14

Clinical Infectious Diseases

Binding Kinetics of Darunavir to Human Immunodeficiency Virus Type 1 Protease Explain the Potent Antiviral Activity and High Genetic Barrier

Inge Dierynck, Mieke De Wit, Emmanuel Gustin, +4

Journal of Virology

ImmunologyMolecular BiologyAntiviral DrugDrug ResistanceBinding Kinetics +16

Potent inhibition of both human interferon-gamma production and biologic activity by the Clara cell protein CC16.

Inge Dierynck, A. Bernard, Harry A. Roels, +1

American Journal of Respiratory Cell and Molecular Biology

Inflammatory Lung DiseaseLung InflammationInnate Immune SystemImmunologyImmunologic Mechanism +18

Hepatitis C Viral Evolution in Genotype 1 Treatment-Naïve and Treatment-Experienced Patients Receiving Telaprevir-Based Therapy in Clinical Trials

Tara L. Kieffer, Sandra De Meyer, Doug J. Bartels, +17

PLoS ONE

The human Clara cell protein: biochemical and biological characterisation of a natural immunosuppressor

Inge Dierynck, A. Bernard, Harry A. Roels, +1

Multiple Sclerosis Journal

Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients

Sandra De Meyer, Erkki Lathouwers, Inge Dierynck, +7

AIDS

Design and Optimization of Tricyclic Phtalimide Analogues as Novel Inhibitors of HIV-1 Integrase

Wim G. Verschueren, Inge Dierynck, Katie Amssoms, +7

Journal of Medicinal Chemistry

Pharmacokinetics, safety and efficacy of darunavir/ritonavir in treatment-experienced children and adolescents

Stéphane Blanche, Rosa Bologna, Pedro Cahn, +8

AIDS

8 EVOLUTION OF TREATMENT-EMERGENT RESISTANT VARIANTS IN TELAPREVIR PHASE 3 CLINICAL TRIALS

J.C. Sullivan, Sandra De Meyer, Doug J. Bartels, +12

Journal of Hepatology

Health SciencesImmunologyClinical TrialsResistance Mutation (Virology)Antiviral Therapy +5